S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT
| Main Authors: | , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2022-06-01
|
| Series: | HemaSphere |
| Online Access: | http://journals.lww.com/10.1097/01.HS9.0000843528.26169.66 |
| _version_ | 1797281784958812160 |
|---|---|
| author | L. Busque M. Harnois N. Szuber R. Delage L. Mollica H. Olney P. Laneuville S. Sirhan G. Cournoyer I. Chamakhi M. Lalancette D. Talbot V. Éthier P. Desjardins S. Assouline |
| author_facet | L. Busque M. Harnois N. Szuber R. Delage L. Mollica H. Olney P. Laneuville S. Sirhan G. Cournoyer I. Chamakhi M. Lalancette D. Talbot V. Éthier P. Desjardins S. Assouline |
| author_sort | L. Busque |
| collection | DOAJ |
| first_indexed | 2024-03-07T17:02:26Z |
| format | Article |
| id | doaj.art-f047b85454dd44c5af37fc7d0c4324d3 |
| institution | Directory Open Access Journal |
| issn | 2572-9241 |
| language | English |
| last_indexed | 2024-03-07T17:02:26Z |
| publishDate | 2022-06-01 |
| publisher | Wiley |
| record_format | Article |
| series | HemaSphere |
| spelling | doaj.art-f047b85454dd44c5af37fc7d0c4324d32024-03-03T03:19:20ZengWileyHemaSphere2572-92412022-06-016606110.1097/01.HS9.0000843528.26169.66202206003-00060S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENTL. Busque0M. Harnois1N. Szuber2R. Delage3L. Mollica4H. Olney5P. Laneuville6S. Sirhan7G. Cournoyer8I. Chamakhi9M. Lalancette10D. Talbot11V. Éthier12P. Desjardins13S. Assouline141 Hematology, Hôpital Maisonneuve-Rosemont, Université de Montréal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal1 Hematology, Hôpital Maisonneuve-Rosemont, Université de Montréal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal1 Hematology, Hôpital Maisonneuve-Rosemont, Université de Montréal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montreal2 Groupe Québécois de Recherche en LMC-NMP, GQR-LMC-NMP, Montrealhttp://journals.lww.com/10.1097/01.HS9.0000843528.26169.66 |
| spellingShingle | L. Busque M. Harnois N. Szuber R. Delage L. Mollica H. Olney P. Laneuville S. Sirhan G. Cournoyer I. Chamakhi M. Lalancette D. Talbot V. Éthier P. Desjardins S. Assouline S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT HemaSphere |
| title | S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT |
| title_full | S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT |
| title_fullStr | S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT |
| title_full_unstemmed | S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT |
| title_short | S159: QUÉBEC CML RESEARCH GROUP ANALYSIS OF TREATMENT PATTERNS IN CHRONIC MYELOGENOUS LEUKEMIA: SWITCHING IS DRIVEN BY INTOLERANCE AND SIMILAR ACROSS TYROSINE KINASE INHIBITORS AND LINES OF TREATMENT |
| title_sort | s159 quebec cml research group analysis of treatment patterns in chronic myelogenous leukemia switching is driven by intolerance and similar across tyrosine kinase inhibitors and lines of treatment |
| url | http://journals.lww.com/10.1097/01.HS9.0000843528.26169.66 |
| work_keys_str_mv | AT lbusque s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT mharnois s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT nszuber s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT rdelage s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT lmollica s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT holney s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT planeuville s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT ssirhan s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT gcournoyer s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT ichamakhi s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT mlalancette s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT dtalbot s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT vethier s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT pdesjardins s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment AT sassouline s159quebeccmlresearchgroupanalysisoftreatmentpatternsinchronicmyelogenousleukemiaswitchingisdrivenbyintoleranceandsimilaracrosstyrosinekinaseinhibitorsandlinesoftreatment |